Livforsakringsbolaget Skandia Omsesidigt Purchases 5,924 Shares of Pfizer Inc. (NYSE:PFE)

Livforsakringsbolaget Skandia Omsesidigt raised its stake in shares of Pfizer Inc. (NYSE:PFE) by 2.7% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 224,651 shares of the biopharmaceutical company’s stock after purchasing an additional 5,924 shares during the period. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Pfizer were worth $6,465,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Front Street Capital Management Inc. raised its position in shares of Pfizer by 4.3% during the 1st quarter. Front Street Capital Management Inc. now owns 5,168 shares of the biopharmaceutical company’s stock valued at $268,000 after buying an additional 215 shares in the last quarter. Castleview Partners LLC raised its position in shares of Pfizer by 2.4% during the 1st quarter. Castleview Partners LLC now owns 12,207 shares of the biopharmaceutical company’s stock valued at $498,000 after buying an additional 287 shares in the last quarter. United Bank raised its position in shares of Pfizer by 0.6% during the 1st quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock valued at $2,416,000 after buying an additional 290 shares in the last quarter. Compton Capital Management Inc. RI raised its position in shares of Pfizer by 0.5% during the 1st quarter. Compton Capital Management Inc. RI now owns 63,891 shares of the biopharmaceutical company’s stock valued at $3,308,000 after buying an additional 300 shares in the last quarter. Finally, GHP Investment Advisors Inc. raised its position in shares of Pfizer by 2.4% during the 4th quarter. GHP Investment Advisors Inc. now owns 13,332 shares of the biopharmaceutical company’s stock valued at $683,000 after buying an additional 307 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 1.1 %

Shares of NYSE:PFE traded down $0.29 during trading on Wednesday, reaching $25.41. 43,790,104 shares of the company were exchanged, compared to its average volume of 42,573,164. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. The business’s fifty day simple moving average is $27.23 and its 200-day simple moving average is $28.79. Pfizer Inc. has a 12-month low of $25.26 and a 12-month high of $41.33. The firm has a market capitalization of $143.86 billion, a PE ratio of 71.36, a P/E/G ratio of 1.18 and a beta of 0.61.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. During the same period last year, the firm earned $1.14 earnings per share. The company’s quarterly revenue was down 41.3% on a year-over-year basis. On average, research analysts anticipate that Pfizer Inc. will post 2.22 EPS for the current year.

Analysts Set New Price Targets

Several analysts have recently issued reports on PFE shares. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Monday. TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a research report on Thursday, January 4th. Finally, Guggenheim assumed coverage on shares of Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 target price on the stock. Twelve investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $36.88.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.